Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Ovarian cancer: a current update

Share :

Ovacome Members' Day

18 May 2019
Published: 24 May 2019
Views: 3548
Rating:
Save
Prof Christina Fotopoulou - Queen Charlotte's and Chelsea Hospital, London, UK

Prof Christina Fotopoulou presents a talk on 'Ovarian cancer: a current update' at the Ovacome Members' Day 2019.

Related Videos

ASCO 2024: Lung cancer highlights
Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...
ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )
26 Jun 2024
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for...
Prof Ignace Vergote - UZ Leuven, Leuven, Belgium
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer ( Prof Ignace Vergote - UZ Leuven, Leuven, Belgium )
7 Nov 2023
2 year recurrence free survival benefit for resectable melanoma treated with...
Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA
2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )
2 Nov 2023
The advantages of IORT for early breast cancer treatment
Dr David Martinez Perez - AUNA, Lima, Peru
The advantages of IORT for early breast cancer treatment ( Dr David Martinez Perez - AUNA, Lima, Peru )
26 Apr 2023
The pros and cons of breast IORT and ultra hypofractionation (FR)
Dr Sofia Rivera - Institut Gustave Roussy, Villejuif, France
The pros and cons of breast IORT and ultra hypofractionation (FR) ( Dr Sofia Rivera - Institut Gustave Roussy, Villejuif, France )
4 Apr 2023
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
28 Mar 2023
Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free...
Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany
Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )
16 Mar 2023
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation...
Dr Jayant Vaidya - University College London, London, UK
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival ( Dr Jayant Vaidya - University College London, London, UK )
9 Mar 2023
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast...
Dr Jayant Vaidya - University College London, London, UK
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer ( Dr Jayant Vaidya - University College London, London, UK )
9 Mar 2023

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation